Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance
Ceftobiprole was non-inferior to ceftriaxone ± linezolid for clinical success at Day 3 according to the current 2020 FDA CABP Guidance.
Authors
- Daniel Ionescu
- Andrew F. Shorr (ORCID: https://orcid.org/0000-0002-4537-8328)
- Jennifer I. Smart (ORCID: https://orcid.org/0000-0002-4310-6599)
- Marc Frederick Engelhardt (ORCID: https://orcid.org/0000-0003-2432-0212)
- Mikael Saulay
- Silke Friedmann
- Mark E. Jones
Institutions
- MedStar Washington Hospital Center (US)
- Washington Hospital (US)
- Basilea Pharmaceutica (Switzerland) (CH)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1371/journal.pone.0326758
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Basilea Pharmaceutica